International Journal of Applied Research
Vol. 2, Issue 1, Part H (2016)
Detection of resistance pattern, extended-spectrum Beta -lactamase producing clinical isolates Escherichia coli and Klebsiella pneumoniae
The incidence of carbapenem resistance among gram-negative bacteria is a major cause of concern which threatens to disrupt therapeutic options. This study document the antibiotics susceptibility pattern of ESBL-producing Escherichia coli and Klebsiella pneumoniae in clinical isolates. 54 isolates of E. coli and 24 isolates of K. pneumoniae were screened as ESBL-producers against any one or more of the cefpodoxime, ceftazidime, cefotaxime, ceftriaxone and aztreonam by Kirby-Bauer disc diffusion method. Norfloxacin and nitrofurantoin were tested only against isolates from urine samples. Highest numbers of ESBL-producing E. coli were detected by cefpodoxime while ceftriaxone showed the least sensitivity. In some cases the isolates produced ESBL against only one of the antibiotics and in some cases more than one. ESBL-producing E. coli isolates showed highest susceptibility to meropenem (94.6%) followed by amikacin (82.6%), and imipenem (90.7%). ESBL-producing K. pneumoniae showed highest susceptibility to meropenem (88.5%) followed by gentamicin & piperacillin-tazobactam (81.6%), and amikacin, ciprofloxacin & levofloxacin (78.2%). Susceptibility of both the organisms to other antibiotics was below 75%. The susceptibility of urinaryrnisolates of E. coli and K. pneumoniae to nitrofurantoin was 81.1% and 96% respectively.
How to cite this article:
Dr. Krishna Kumar Patel, Dr. Sarita Patel, Dr. Chandrakishor Chandrawanshi, Dr. Vikas Kumar Jain, Deepali Rajwade, Dr. Santosh Agrawal, Vishal Kahre, Medha Singh. Detection of resistance pattern, extended-spectrum Beta -lactamase producing clinical isolates Escherichia coli and Klebsiella pneumoniae. Int J Appl Res 2016;2(1):523-525.